Conference Coverage
Meetings
View past articles
Eosinophilic esophagitis: A year in review
-
by Joan W. Chen, MD, MS
Diet remains the only therapy targeting the cause of EoE and offers a potential drug-free remission.
GLP-1 therapy in Crohn's disease: Fewer steroids, hospitalizations
-
by Doug Brunk
“What stood out most was the consistent association between GLP-1 receptor agonist use and lower steroid dependence."
FMT improves IBD remission, meta-analysis suggests
-
by Doug Brunk
Researchers evaluated 7 trials involving 542 patients with UC or CD.
Upadacitinib in pediatric IBD: 52-week results
-
by Doug Brunk
Response in those with ulcerative colitis was especially strong.
Four reasons to add intestinal ultrasound to your practice
-
by Doug Brunk
“It's really made its way already into the mainstream of IBD care,” Dr. Rishika Chugh said.
Expert spotlights advances in ulcerative colitis treatment
-
by Doug Brunk
“Appendicectomy is a viable and safe strategy for reducing the relapse rate in patients with UC compared to standard medical therapy alone,” Dr. Kara De Felice said.
New Crohn's data spotlight promising therapies
-
by Doug Brunk
Beyond drugs, interest is growing in diet-based treatments.
Hospital care for IBD gets practical refresh
-
by Doug Brunk
“IBD experts around the country are receiving many more calls from community gastroenterologists for advice treating their hospitalized patients,” Dr. Shirley Cohen-Mekelburg said.
MRI-based standard may predict outcomes in perianal Crohn's
-
by Doug Brunk
The TopCLASS definition identifies healing based on three criteria.
Postoperative Crohn’s: What’s changed?
-
by Doug Brunk
The concept of reusing anti-TNF therapy after surgery is gaining traction.
Creeping fat in Crohn's may turn harmful
-
by Doug Brunk
Even though it is common, the condition has not been studied much.
Surgical strategy for perianal Crohn's: Lessons from TOpCLASS
-
by Doug Brunk
MRI-guided staging helps reshape surgical decision-making.
Edulis Therapeutics takes top honors at AGA Shark Tank Pitch competition
-
by Doug Brunk
The company has developed a drug-delivery system that implants medication directly into the GI tract.
Investigational endoscopic therapy maintains weight after GLP-1 discontinuation
-
by Doug Brunk
The treatment could provide an "off-ramp for patients who either can't or don't want to be on these drugs long-term."
Early-onset CRC deaths rising fast, analysis finds
-
by Doug Brunk
“Rectal cancer is striking younger Americans earlier and killing faster."
Late-night eating, stress tied to bowel issues
-
by Doug Brunk
Meal timing “might magnify the impact of stress on the microbiome via the gut-brain axis."
Autoimmune hepatitis linked to significantly higher risk of extrahepatic cancers
-
by Doug Brunk
“While autoimmune hepatitis is known to increase liver cancer risk, its association with cancers outside the liver remains poorly defined."
AI-assisted colonoscopy linked to higher adenoma detection
-
by Doug Brunk
A real-world analysis of more than 1.5 million matched patients links AI-assisted colonoscopy to a 47% reduction in interval colorectal cancer.
Antibiotics tied to early adenoma risk, study finds
-
by Doug Brunk
A nested case-control study of nearly 24,000 patients found cumulative exposure and timing both matter.
Physician triage changed management in nearly 1 in 4 GI referrals
-
by Bob Alaburda
Specialists found that 47% of referrals were flagged as urgent or STAT, yet only 23% required care within a two-week window.
Higher-dose advanced therapies linked to better UC remission
-
by Doug Brunk
“In UC, undertreatment can carry major consequences, including persistent inflammation, steroid exposure, hospitalization, and surgery.”
Largest cohort to date clarifies natural history of hereditary pancreatitis
-
by Bob Alaburda
“Our results support the need for long-term follow-up of all individuals carrying pathogenic trypsinogen gene variants, not only those with chronic pain or recurrent pancreatitis.”
AGA president maps innovation agenda at DDW® 2026
-
by Doug Brunk
Dr. Lawrence Kim called for a unified approach to innovation spanning AI, genomics, workforce development, and policy advocacy.
AI score may boost UC trial efficiency
-
by Doug Brunk
Continuous endoscopic metric may detect treatment effects with fewer patients.
Genetic risk for colorectal cancer growing, analysis shows
-
by Bob Alaburda
“Genetic risk stratification may be increasingly useful in today's population, especially when applied at younger ages.”
Interventional endoscopy roughly doubles per-case emissions
-
by Doug Brunk
“As climate change continues to reshape our healthcare systems, conscientious materials purchasing, optimized recycling and processing, and continual endoscopy suite audits can mitigate overall waste and reduce environmental impact.”
Dual-pathway co-antibody therapy shows promise in refractory IBD
-
by Noah Levine
Dual inhibition of TNF-α and IL-23 pathways yields superior outcomes vs monotherapy in phase 2b Crohn’s and UC trials.
Cholangitis trial supports stopping antibiotics 24 hours after drainage
-
by Noah Levine
In a 413-patient randomized trial, a single-day course matched the guideline-recommended four to seven days for clinical cure.
Nonendoscopic screening detects Barrett's esophagus in at-risk veterans without GERD
-
by Julie Greenbaum
Swallowable cell-collection device showed 100% sensitivity in veterans lacking classic reflux symptoms.
AI liquid biopsy flags occult metastases in ICC before surgery
-
by Julia Cipriano
EXOMIC assay may identify candidates for neoadjuvant therapy and improve preoperative risk stratification.
Late post-colonoscopy cancers tied to detection rate
-
by Julia Cipriano
Ten-year data suggest the protective effect of a high adenoma detection rate persists well beyond four years.
Metabolic disease burden tied to worse outcomes in untreated chronic hepatitis B
-
by Alun Evans
Diabetes alone was linked to higher liver cancer risk and mortality in REAL-B cohort.
Better onboarding may help GI practices retain APPs
-
by Doug Brunk
Practical strategies from GI experts focus on mentorship, staged autonomy, and avoiding early burnout.
ESMR-L found noninferior to ESD in rectal NETs
-
by Julie Greenbaum
Randomized trial shows comparable resection with shorter procedures and lower costs.
Switching to subcutaneous infliximab may cut treatment failure in IBD
-
by Bob Alaburda
Randomized trial finds 48-week treatment failure dropped from 40% to 15% after switching from IV.
Thiopurines can be safely stopped when switching to subcutaneous infliximab, trial finds
-
by Olivia Anderson
MINIMISE trial found no rise in antidrug antibodies or disease activity at 24 weeks after withdrawal.
Study supports sex- and comorbidity-based cutoffs for stopping Barrett's surveillance
-
by Alun Evans
“Most physicians make future surveillance decisions heavily based on perceived risk for EAC without considering … life expectancy.”
